# PATHWAYS Clinical Trial Update Released > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/pathways-clinical-trial-update-released/ > **Published:** 2026-06-19T12:17:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:36-04:00 > **Clinical Summary:** PATHWAYS clinical trial cannabis outcomes—UK prospective study examining efficacy, safety, and real-world patient outcomes. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchPolicySafetyCBDTHCNeurology[Mental Health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) Dr. Caplan’s Take “The PATHWAYS trial represents an important step in generating rigorous human evidence around [cannabis therapeutics](https://cedclinic.com/firearms-regulatory-guidance-cannabis/), though we’ll need to see the full peer-reviewed results before we can meaningfully incorporate any new findings into clinical practice—right now, what matters most is that we’re finally conducting the kind of systematic research that has been missing from this field.” Clinical Perspective 🔬 While large-scale [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) like PATHWAYS provide essential evidence for cannabis-based therapeutics in controlled UK settings, the simultaneous enforcement operations highlighted in this update underscore the disconnect between emerging [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and current legal restrictions that complicate [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) and research recruitment. Healthcare providers should recognize that trial participants may represent a select population with specific indications and comorbidities, potentially limiting generalizability to broader patient populations encountered in routine practice. The regulatory landscape remains fragmented globally, and even positive trial outcomes may take years to translate into approved medications or clinical guidance, creating uncertainty in how to counsel patients currently seeking cannabis for therapeutic purposes outside research protocols. Clinicians should remain informed about PATHWAYS results while maintaining realistic expectations about timelines for evidence integration into standard practice, and in the interim, continue documenting patient requests for [cannabis therapeutics](https://cedclinic.com/firearms-regulatory-guidance-cannabis/) as a signal of unmet clinical needs in their populations. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20PATHWAYS%20Clinical%20Trial%20Update%20Released%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59672)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59672)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20PATHWAYS%20Clinical%20Trial%20Update%20Released%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59672)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [In the Mix: 39 More Articles — June 16, 2026](https://cedclinic.com/39-cannabis-articles-clinical-relevance-june-16-2026/) - [The First Cannabis Drug to Earn FDA Breakthrough Therapy Status for Pain`](https://cedclinic.com/fda-breakthrough-therapy-ver-01-cannabis-chronic-back-pain/) - [Europe’s Medical Marijuana Market Positioned for Explosive Multi-Billion Dollar Growth …](https://cedclinic.com/europes-medical-marijuana-market-positioned-for-explosive-multi-billion-dollar-growth/) 📰 Source: [https://www.miragenews.com/pathways-clinical-trial-update-released-1695729/](https://www.miragenews.com/pathways-clinical-trial-update-released-1695729/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).